May 21 |
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
|
May 20 |
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
|
May 9 |
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
|
May 7 |
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
|
Apr 30 |
PureTech Health plc (NASDAQ:PRTC) Q4 2023 Earnings Call Transcript
|
Apr 26 |
PureTech Health plc (PRTC) Q4 2023 Earnings Call Transcript
|
Apr 25 |
PureTech GAAP EPS of -$0.24, revenue of $3.33M
|
Apr 25 |
PureTech Announces Annual Results for Year Ended December 31, 2023
|
Apr 18 |
PureTech Health: Notice of Results
|
Apr 16 |
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
|